Soquelitinib

Soquelitinib (CPI-818) is a small-molecule drug developed by Corvus Pharmaceuticals. The sponsor describes its target as ITK (interleukin-2-inducible T-cell kinase), which OnCo does not yet have a target page for. The sponsor states: An oral, selective ITK inhibitor that promotes Th1 helper cell development while suppressing Th2 and Th17 cells, and can shift differentiation toward regulatory T cells. ClinicalTrials.gov describes the intervention as: Soquelitinib 200 mg tablets will be taken by mouth two times a day. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06561048 (Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma), in peripheral T-cell lymphomas. The largest, NCT06561048, plans to enrol 150 participants with primary completion expected 2027-11. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.